Quantification of low-abundance antibody by-products
The SPR method addresses the challenge of detecting antibody-related by-products with increased avidity by leveraging differential dissociation kinetics, providing sensitive quantification and control over safety risks in therapeutic applications.
Patent Information
- Application Number
- JP2024531273
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-11-25
- Filing Date
- 2022-11-18
- Publication Date
- 2024-12-03
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Conventional SPR methods struggle to distinguish between different binding events with similar mass changes, making it difficult to detect and quantify antibody-related by-products with increased avidity, which can cause undesirable side effects in therapeutic applications.
A method utilizing surface plasmon resonance (SPR) to detect and quantify antibody-related by-products by exploiting their increased avidity through differential dissociation kinetics, involving immobilization of antigens at specific densities, extended binding times, and differential dissociation phases to capture residual binding signals.
Enables sensitive detection and quantification of antibody-related by-products below the limits of established methods, effectively monitoring and controlling potential safety risks associated with increased avidity, such as non-specific T cell activation.
Smart Images

Figure 2024544607000001_ABST
Abstract
Description
[Technical field]
[0001] The present invention is in the field of analytical methods. The present invention relates to a method for determining and quantifying antibody-related by-products (e.g. heteromeric multispecific antibodies) resulting from incorrect pairing of antibody chains (especially resulting in undesirable increased avid binding properties of the by-products). Such by-products may have increased biological activity and may result in undesirable side effects compared to correctly assembled multispecific antibodies. [Background technology]
[0002] Surface Plasmon Resonance (SPR) is an optical technique utilized to detect molecular interactions. Binding of a mobile molecule (analyte) to a molecule (ligand) immobilized on a thin metal film changes the refractive index of the film. The extinction angle of the reflected light after polarized light impinges on the film changes and is monitored as a change in detector position relative to the decrease in reflected intensity (Surface Plasmon Resonance phenomenon). As the method strictly detects mass, there is no need to label the interacting components, thus eliminating possible changes in their molecular properties (Drescher, DG et al. Meth. Mol. Biol. 493 (2009) 323-343 (Non-Patent Document 1)).
[0003] SPR binding analysis methods are used to study molecular interactions. One interaction partner is immobilized directly by chemical reaction (e.g., amine coupling reaction) or indirectly by forming a binding pair (e.g., biotin-streptavidin) on a sensor chip. The chip is then inserted into the flow chamber of an SPR instrument, for example available from BIAcore (BIAcore, Uppsala, Sweden). When the flow-through analyte, which is the second interaction partner, is added to the chamber, it binds to the immobilized first interaction partner, causing a small change in the refractive index at the gold surface. This change can be quantified with high precision. The binding affinity can be obtained from the ratio of the rate constants, resulting in a direct characterization of the protein-protein interaction (Drescher, DG et al. Meth. Mol. Biol. 493 (2009) 323-343 (Non-Patent Document 1)).
[0004] Unfortunately, the universal nature of SPR detection also constitutes a fundamental limitation: since all binding events give rise to a similar refractive index signal, it is not possible to distinguish between different binding events that result in similar mass changes. One area of rapidly growing interest where the information content of conventional SPR can be limited is the study of bispecific binders (e.g., bispecific antibodies). Here, specialized assay formats are required, and the binding of the two species must be studied sequentially, rather than in parallel. A relevant case is the competition-based assay, where an analyte molecule binds to a surface species at the same or similar binding site. In principle, a competition assay could be performed using SPR by calculating the residual binding. However, this is not trivial for small molecule competitors, since slight concentration differences in the organic solvent vehicle (i.e., DMSO) between samples can have a significant negative effect on the achievable signal-to-noise ratio and hinder the ability to accurately determine the residual binding signal (Eng, L. et al., Biochem. Biophys. Res. Comm. 497 (2018) 133-138 (Non-Patent Document 2)).
[0005] Eng et al. (supra) reported a label-enhanced SPR (LE-SPR) technique to increase the information content of SPR by enabling the qualitative discrimination and quantitative monitoring of two different simultaneously binding species using a standard commercially available single-wavelength SPR instrument. LE-SPR is based on the labeling of binding molecules with special dye labels combined with readout of the entire SPR dip during the binding reaction and software-based shape analysis. They demonstrate three examples of dual-species detection: i) accurate quantitative determination of two different species in a mixed bulk solution sample; ii) qualitative decomposition of a conventional sensorgram of two different simultaneously binding species into separate binding curves of the two species followed by faithful reconstruction of the original sensorgram; and iii) simultaneous determination of the binding dissociation constants of two different species in a mixture binding to a protein on a surface.
[0006] T cell-dependent bispecific antibodies (TDB or TCB) are promising cancer immunotherapies that recruit patients' T cells to kill cancer cells. The number of TDBs in clinical trials is increasing, indicating that their therapeutic potential is widely recognized. Due to the fact that TDBs bind and activate T cells via their anti-CD3 (aCD3) arms, aCD3 homodimers (aCD3 HD) and high molecular weight species (HMWS) are product-associated impurities that pose a potential safety risk by causing nonspecific T cell activation via bivalent binding and dimerization of the T cell receptor (TCR). This nonspecific (also known as target cell-independent) T cell activation can induce cytokine secretion and cause unwanted immune responses in patients. Nonspecific T cell activation by aCD3 HD is different from T cell activation by TDB, which is an unwanted activity and ultimately kills the target tumor cells. Therefore, it is important to control the level of aCD3 HD in TDB preparations, and a highly sensitive assay is required to enable its quantification (Lee, HY et al., Nature Sci. Rep. 9 (2019) 3900 (Non-Patent Document 3)).
[0007] To monitor and control the level of non-specific T cell activation, Lee et al. (supra) reported a sensitive and quantitative cell-based T cell activation assay that can detect aCD3 HD in TDB formulations by taking advantage of its ability to activate T cells in the absence of target cells.
[0008] WO 2020 / 200941 (Patent Document 1) describes a heterodimeric fusion polypeptide comprising a first protein portion and a second protein portion, the first protein portion and the second protein portion being first and second antigens of a bispecific antibody comprising a first binding site that specifically binds to the first protein portion and a second binding site that specifically binds to the second protein portion, the first protein portion being fused to the N-terminus of a first antibody heavy chain Fc region polypeptide of the IgG1 subtype, the second protein portion being fused to the N-terminus of a second antibody heavy chain Fc region polypeptide of the IgG1 subtype, and the first and second antigens of a bispecific antibody comprising a first binding site that specifically binds to the first protein portion and a second binding site that specifically binds to the second protein portion. and a second heavy chain Fc region polypeptide, which form a disulfide-bonded heterodimer, one or both of the heavy chain Fc region polypeptides comprising a tag at their C-terminus for immobilization on a solid phase, and the first and second Fc region polypeptides comprising the mutations T366W and T366S / L368A / Y407V, respectively; and use of the fusion polypeptide for determining the avidity-based binding strength of a bispecific antibody comprising a first binding site that specifically binds to a first antigen and a second binding site that specifically binds to a second antigen, to a first antigen and a second antigen, by surface plasmon resonance.
[0009] Amaral, M. et al. report engineering techniques and bioanalysis of multispecific antibody formats (J. Appl. Bioanal. 2020(6)26-51 (Non-Patent Document 4)).
[0010] US Patent Application Publication No. 2017 / 003295 (Patent Document 2) reports an SPR-based bridge assay format for determining the biological activity of multivalent, multispecific molecules.
[0011] WO 2014 / 177460 (Patent Document 3) reports human FcRn binding modified antibodies and methods of use.
[0012] JP 2020 / 202848 A (Patent Document 4) reports modified antigen-binding polypeptide constructs and uses thereof. [Prior art documents] [Patent documents]
[0013] [Patent Document 1] International Publication No. 2020 / 200941 [Patent Document 2] US Patent Application Publication No. 2017 / 003295 [Patent Document 3] International Publication No. 2014 / 177460 [Patent Document 4] JP 2020 / 202848 A [Non-patent literature]
[0014] [Non-Patent Document 1] Drescher, DG et al. Meth. Mol. Biol. 493 (2009) 323-343 [Non-Patent Document 2] Eng, L. et al., Biochem.Biophys.Res.Comm.497(2018)133-138 [Non-Patent Document 3] Lee, HY et al., Nature Sci. Rep. 9 (2019) 3900 [Non-Patent Document 4] Amaral, M. et al., J.Appl.Bioanal.2020(6)26-51 Summary of the Invention
[0015] Herein, we report a method for the determination and / or quantification of therapeutic antibody-related by-products based on the difference in apparent binding affinity between a correctly assembled therapeutic antibody and a therapeutic antibody-related by-product, i.e., based on the increased binding avidity.
[0016] Without being bound by this theory, it is hypothesized that any antibody-related by-products with increased binding valency compared to a correctly assembled antibody can be determined and / or quantified using the approaches described herein.Similarly, any method suitable for determining the difference in apparent binding affinity can be used, such as ELISA and SPR.
[0017] Antibody-related by-products with increased apparent binding avidity contain more binding sites for their respective targets (i.e., antigens) than properly assembled antibodies, e.g., two binding sites instead of one, four binding sites instead of two, etc.
[0018] The principles of the assays described herein may be applied to various bioassays using different detection methods such as ELISA (enzyme-linked immunosorbent assay), SPR (surface plasmon resonance) or BLI (biolayer interferometry).
[0019] For example, the apparent affinity difference due to the increased binding avidity between an antibody and a valency-increased antibody-related by-product can be quantified by ELISA, in which the antibody-ligand interaction is dissociated by applying appropriate washing conditions, leaving the by-product-ligand complex intact. Furthermore, the signal obtained is proportional to the content of multivalent by-product in the sample. The amount can be quantified using a calibration curve.
[0020] Similarly, SPR can be used to exploit by-product specific interaction properties that result in different dissociation rates that result in time-dependent differences in the residual binding signal.
[0021] More particularly, in one aspect, the present invention relates to an SPR-based assay that allows for the determination of amounts of (bispecific) antibody-related by-products that were previously below the detection limits of established quantification methods.
[0022] The method according to the invention is particularly suitable for the determination and / or quantification of antibody-related by-products with high binding valency to a target.
[0023] For the formation of bispecific antibodies, different approaches are known to promote heterodimer formation. One is the knob-into-hole design (e.g., WO 96 / 027011; Ridgway, JB et al., Protein Eng. 9 (1996) 617-621; Merchant, AM et al., Nat. Biotechnol. 16 (1998) 677-681; WO 98 / 050431). During the development of bispecific antibodies, conjugates that are more likely to cause adverse events are usually linked to knob chains in a knob-into-hole antibody format. The formation of knob-knob homodimers is sterically unfavorable compared to the formation of hole-hole homodimers. This results in very small amounts of mispaired knob-knob molecules being brought about as antibody-related by-products during antibody production, since this antibody composition is unfavorable.
[0024] Although these knob-knob by-products constitute a small fraction of the antibody product, they need to be intensively monitored, as they may cause adverse side effects, e.g., toxicological side effects, or reduce the efficiency of the drug, e.g., by failing to perform the intended biological action. These undesirable events are caused by the enhancement of drug-target complex stability by avidity (avido binding).
[0025] The present invention is based, at least in part, on the discovery that such increased avidity can be exploited in SPR assays to detect lower by-product concentrations than were previously detectable by established methods such as SEC or MS. While established methods use residual binding to the isolated drug, the method according to the present invention uses enrichment by avidity that is not used in other quantification methods.
[0026] In the SPR method according to the invention, the antibody target, i.e., the antigen, is immobilized on the SPR sensor chip. Then, the sample containing the antibody and antibody-related by-products to be detected is injected. This results in the formation of an antibody-target complex on the sensor surface. A buffer solution without the antibody and without the antibody-related by-products can then be injected into the system to dissociate the antibody-target complex. This results in a slower dissociation profile for the antibody-related by-products compared to the dissociation of a properly assembled antibody. This slower dissociation results in a stronger SPR binding signal after a defined dissociation time compared to an antibody sample without antibody-related avidity-binding by-products. This stronger signal is the residual binding due to the avidity of the antibody-related homodimer by-products. This allows the amount of antibody-related homodimer avidity-binding by-products present in the sample, and thus ultimately the concentration of antibody-related avidity-binding homodimer by-products, to be quantified with a very low detection limit.
[0027] The present invention is based, at least in part, on the finding that the antibody target (= antigen) must be immobilized at a minimum density or density range depending on the format of the multispecific antibody, e.g. bispecific antibody, to be tested. In a particular embodiment, the antibody target must be immobilized at at least 1000 RU. In a preferred embodiment, the target is immobilized at at least 2000 RU. In a particular embodiment, the target is immobilized at at least 4000 RU. In a particular embodiment, the target is immobilized at 2000-4000 RU.
[0028] The present invention is based, at least in part, on the discovery that the detection limit of the method can be reduced by increasing the antibody injection time, since antibody-related by-products capable of avid binding accumulate on the chip surface during the binding time. In a particular embodiment, the binding time is at least 240 seconds. In a particular embodiment, the binding time is at least 300 seconds. In a preferred embodiment, the injection time is at least 360 seconds. In a particular embodiment, the binding time is at least 420 seconds.
[0029] The present invention is based, at least in part, on the discovery that the difference between antibody complex stability and antibody-related by-product complex stability on SPR chip can be used to quantify antibody-related by-products.In a preferred embodiment, the dissociation time that residual binding is determined is at least 1200 seconds.In a particular embodiment, the dissociation time that residual binding is determined is at least 1800 seconds.
[0030] Residual binding depends on the amount or proportion of antibody-associated avidin-conjugated by-product in the sample and the stability of the complex between the antibody-associated by-product and the target, ie, the difference in complex stability compared to a properly assembled antibody.
[0031] Therefore, if the residual binding is low, the assay conditions can be adjusted to increase the residual binding.This can be done by various means known to those skilled in the art, based on the knowledge of the present invention, for example, on the general knowledge of the thermodynamic and kinetic properties of the isolated antibody and the antibody-related by-products detected.Exemplary means are listed in the following table.
[0032] TIFF2024544607000002.tif69130
[0033] One aspect according to the invention is a method for determining misassociated antibody by-products in a sample containing correctly associated antibodies and misassociated antibody by-products, comprising the steps of: The correctly assembled antibody and the misassembled antibody by-products bind to the (first) target, The misassembled antibody by-products contain more binding sites for the target than the correctly assembled antibody, The method comprises: i) immobilizing the target on the surface of the SPR chip at a high density, preferably at least 1000 RU, more preferably at least 1500 RU, and most preferably at least 2000 RU; ii) applying a buffer solution containing correctly assembled antibodies (as the only species that bind to the target) to the surface obtained in step i), preferably for at least 5 minutes, more preferably for at least 7 minutes, most preferably for at least 10 minutes, at a flow rate preferably of 30 μL / min or less (in the range of 50 μL / min to 5 μL / min), more preferably of 25 μL / min or less (in the range of 40 μL / min to 7.5 μL / min), most preferably of 20 μL / min or less (in the range of 30 μL / min to 10 μL / min) to generate a loaded surface; iii) applying a (buffer) solution free of target-binding compounds (i.e. free of correctly assembled antibodies and of misassembled antibody by-products) to the loaded surface obtained in step ii) for preferably at least 7.5 minutes, more preferably at least 15 minutes, most preferably at least 20 minutes, and recording the decay of the SPR signal; iv) optionally regenerating the SPR surface; v) applying a (buffered) sample solution suspected of containing misassociated antibody by-products to the SPR surface obtained as in step i) or to the regenerated SPR surface of step iv) at a flow rate of preferably 30 μL / min or less (in the range of 50 μL / min to 5 μL / min), more preferably 25 μL / min or less (in the range of 40 μL / min to 7.5 μL / min), most preferably 20 μL / min or less (in the range of 30 μL / min to 10 μL / min), for at least 5 minutes, more preferably at least 7 minutes, most preferably at least 10 minutes, to generate a loaded surface; vi) applying a (buffer) solution free of target binding compounds to the loaded surface obtained in step v) for preferably at least 7.5 minutes, more preferably at least 15 minutes, most preferably at least 20 minutes, and recording the decay of the SPR signal, vii) determining the misassociated antibody by-products if the SPR signal determined in step vi) exceeds / remains above the SPR signal determined in step iii) at least 7.5 minutes after the start of application of the (buffered) solution without the compound that binds to the target, more preferably at least 15 minutes after the start of application of the (buffered) solution without the compound that binds to the target, most preferably at least 20 minutes after the start of application of the (buffered) solution without the compound that binds to the target. The method includes:
[0034] One aspect of the invention is a method for determining bispecific antibody misassociation by-products in a sample containing correctly assembled bispecific antibodies and bispecific antibody misassociation by-products using surface plasmon resonance, comprising: A correctly assembled bispecific antibody contains exactly one binding site for the first antigen and one or more binding sites for the second antigen, i.e. a bispecific antibody has one binding site which (specifically) binds to the first antigen and one or more binding sites which (specifically) bind to the second antigen; The misassociated by-product of a bispecific antibody contains two or more binding sites for a first antigen and zero to two binding sites for a second antigen, A correctly assembled bispecific antibody is a heterodimer and a misassembled bispecific antibody is a homodimer with respect to the Fc region, preferably the heterodimer is formed by the knob-into-hole method, The method comprises: i) immobilizing a first antigen on the surface of at least one flow cell of the SPR chip at a high density, preferably at least 1000 RU, more preferably at least 1500 RU, and most preferably at least 2000 RU; ii) applying a buffer solution comprising the isolated bispecific antibody as the only species binding to the antigen (or a reference standard comprising the correctly assembled bispecific antibody and an upper limit amount of a misassembled bispecific antibody by-product) to at least one flow cell obtained in step i), preferably for at least 5 minutes, more preferably for at least 7 minutes, and most preferably for at least 10 minutes, at a flow rate of preferably 30 μL / min or less (in the range of 50 μL / min to 5 μL / min), more preferably 25 μL / min or less (in the range of 40 μL / min to 7.5 μL / min), and most preferably 20 μL / min or less (in the range of 30 μL / min to 10 μL / min); iii) applying a buffer solution free of compounds that bind to the antigen (i.e. free of bispecific antibodies and misassociated by-products of bispecific antibodies) to at least one flow cell obtained in step ii), preferably for at least 7.5 minutes, more preferably for at least 15 minutes, most preferably for at least 20 minutes, recording the decay of the SPR signal, and then optionally regenerating at least one flow cell; iv) applying a buffered sample solution suspected of containing bispecific antibody misassociated by-products (or containing more than an upper limit amount of bispecific antibody misassociated by-products) to at least one flow cell obtained as in step i) or the regenerated flow cell obtained in step iii) for preferably at least 5 minutes, more preferably at least 7 minutes, and most preferably at least 10 minutes at a flow rate of preferably 30 μL / min or less (in the range of 50 μL / min to 5 μL / min), more preferably 25 μL / min or less (in the range of 40 μL / min to 7.5 μL / min), and most preferably 20 μL / min or less (in the range of 30 μL / min to 10 μL / min); v) applying a buffer solution free of antigen-binding compounds (i.e. free of bispecific antibodies and misassociated bispecific antibody by-products) to at least one flow cell obtained in step iv), preferably for at least 7.5 minutes, more preferably at least 15 minutes, and most preferably at least 20 minutes, and recording the decay of the SPR signal; vi) determining the presence of misassociated by-products of the bispecific antibody if, after the start of application of the buffered solution not containing compounds that bind to the antigen (i.e. not containing the bispecific antibody or misassociated by-products of the bispecific antibody), the SPR signal determined in step v) exceeds the SPR signal determined in step iii), preferably at least 7.5 minutes, more preferably at least 15 minutes, most preferably 20 minutes, after the start of application of the (buffered) solution not containing compounds that bind to the target. The method includes:
[0035] One aspect of the invention is a method for determining avid-binding by-products of a bispecific antibody in a sample containing a properly assembled bispecific antibody and one or more avid-binding by-products of the bispecific antibody using surface plasmon resonance, comprising: A properly assembled bispecific antibody contains one or more binding sites for a first antigen and one or more binding sites for a second antigen, the avid-conjugated by-product of the bispecific antibody contains two or more, and many more, binding sites for the first antigen than the properly assembled bispecific antibody; The method comprises: i) applying a loading solution containing the correctly assembled bispecific antibody to an SPR surface on which a first antigen has been immobilized at at least 1000 RU to generate an SPR signal, and then applying a dissociation solution that does not contain a compound that binds to the first antigen to the SPR chip and recording the decay of the SPR signal; ii) applying a sample solution suspected of containing an avidin-binding by-product of the bispecific antibody to an SPR surface having a first antigen immobilized thereon at least 1000 RU to generate an SPR signal, and then applying a dissociation solution that does not contain the compound that binds to the first antigen to the SPR chip and recording the decay of the SPR signal; iii) determining the avidin-binding by-products of the bispecific antibody when the decay of the SPR signal determined in step ii) is slower than the decay of the SPR signal determined in step i); The method includes: DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0036] Detailed Description of the Invention Embodiments The present invention relates to a method for determining homodimeric avid-binding by-products of a bispecific antibody in a sample containing a correctly assembled heterodimeric affine-binding bispecific antibody and a misassembled homodimeric avid-binding by-product of the bispecific antibody using surface plasmon resonance, where the correctly assembled heterodimeric affine-binding bispecific antibody comprises one or more binding sites for a first antigen and one or more binding sites for a second antigen, the misassembled homodimeric avid-binding by-product of the bispecific antibody comprises two or more, but at least more, binding sites for the first antigen than the correctly assembled bispecific antibody, the correctly assembled bispecific antibody is a heterodimer, and the misassembled bispecific antibody is a homodimer, and the presence of homodimeric avid-binding by-products is determined if residual binding (i.e., a stronger SPR signal) can be determined in the dissociation phase of the SPR analysis.
[0037] The present invention is based, at least in part, on the discovery that the increased avidity of misassociated multispecific antibodies can be exploited in SPR assays to detect lower by-product concentrations than were previously detectable by established methods such as SEC or MS. While established methods use residual binding to the isolated drug, the method according to the invention uses enrichment by avidity that is not used by other quantification methods.
[0038] The present invention therefore relates to a method for the determination or / and quantification of therapeutic antibody related by-products based on the difference in apparent binding affinity between a correctly assembled therapeutic antibody and a therapeutic antibody related by-product, i.e. based on an increase in binding avidity.
[0039] The method according to the invention allows the determination of the presence of antibody-related by-products that have increased binding valency compared to a correctly assembled antibody.
[0040] In other words, antibody-related by-products with increased apparent binding avidity contain more binding sites for their respective targets (i.e., antigens) than properly assembled antibodies, e.g., two binding sites instead of one, four binding sites instead of two, etc.
[0041] definition The term "about" refers to a range of ±20% of the numerical value that follows. In certain embodiments, the term "about" refers to a range of ±10% of the numerical value that follows. In certain embodiments, the term "about" refers to a range of ±5% of the numerical value that follows.
[0042] "Affinity" or "binding affinity" refers to the strength of the sum of non-covalent interactions between a single binding site of a molecule (e.g., an antibody) and its binding partner (= target) (e.g., an antigen). Unless otherwise indicated, as used herein, "binding affinity" refers to the inherent binding affinity that reflects a 1:1 interaction between members of a binding pair (e.g., an antibody and a target (antigen)). The affinity of a molecule X for its partner Y is generally determined by the dissociation constant (K D ), which can be expressed as the dissociation rate constant and the association rate constant (k off and k on ) is the ratio of the rate constants. Thus, equivalent affinities may include different rate constants, as long as the ratio of the rate constants remains the same. Affinity may be measured by common methods known in the art, including the methods described herein. A particular method for measuring affinity is surface plasmon resonance (SPR).
[0043] The term "antibody" is used herein to define at least heterodimeric multispecific antibodies (eg, bispecific antibodies, trispecific antibodies).
[0044] A Y-shaped full-length antibody generally comprises two so-called light chain polypeptides (light chains) and two so-called heavy chain polypeptides (heavy chains). Each of the heavy and light chain polypeptides comprises a variable domain (variable region) (generally the amino-terminal portion of the polypeptide chain) that contains a binding region capable of interacting with an antigen. The pairing of a light chain variable domain and a heavy chain variable domain forms the binding site of the antibody. Each of the heavy and light chain polypeptides comprises a constant region (generally the carboxyl-terminal portion). The constant region of the heavy chain mediates the binding of the antibody to i) cells bearing Fc gamma receptors (FcγR), such as phagocytes, or ii) cells bearing fetal Fc receptors (FcRn), also known as Brambell receptors. The constant region of the heavy chain also mediates the binding to several factors, including factors of the classical complement system, such as the (C1q) component. The constant domains of an antibody heavy chain comprise the CH1, CH2 and CH3 domains, whereas the light chain comprises only one constant domain, CL, which can be of the kappa or lambda isotype.
[0045] The "class" of an antibody refers to the type of constant domain or region carried by its heavy chain. There are five major classes of antibodies: IgA, IgD, IgE, IgG, and IgM, some of which have subclasses (isotypes), e.g., IgG 1 , IgG 2 , IgG 3 , IgG 4 , IgA 1 , and IgA 2 The heavy-chain constant domains that correspond to the different classes of immunoglobulins are called α, δ, ε, γ, and μ, respectively.
[0046] The term "binding (to an antigen)" refers to the binding of an antibody to its antigen in an in vitro assay, and in certain embodiments, in a binding assay in which the target is bound to a surface and the binding of the antibody to the target is measured by surface plasmon resonance (SPR). Binding refers, for example, to measuring the binding ability of an antibody to target A or target B, or to a capture molecule, for example, an anti-human Fab capture to an antibody.
[0047] As used herein, the term "monoclonal antibody" refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies constituting the population are identical and / or bind to the same epitope, with the exception of possible variant antibodies that contain, for example, naturally occurring mutations or arise during the production of the monoclonal antibody preparation, such variants generally being present in minor amounts. In contrast to polyclonal antibody preparations that typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody of a monoclonal antibody preparation is directed against a single determinant on the antigen. Thus, the modifier "monoclonal" denotes the character of the antibody obtained from a substantially homogeneous population of antibodies, and is not constructed to require production of the antibody by any particular method. For example, the monoclonal antibodies used in accordance with the present invention may be produced by a variety of techniques, including, but not limited to, hybridoma methods, recombinant DNA methods, phage display methods, and methods utilizing transgenic animals containing all or part of the human immunoglobulin loci, and such methods and other exemplary methods for producing monoclonal antibodies are described herein.
[0048] The term "valency" as used in this application refers to the presence of a particular number of binding sites in an antibody. Thus, the terms "bivalent", "tetravalent" and "hexavalent" refer to the presence of two, four and six binding sites in an antibody, respectively. A bispecific antibody, for example, contains at least two binding sites that specifically bind to different targets.
[0049] The term "binding affinity" refers to the strength of the interaction between a single binding site and its respective target. Experimentally, affinity can be determined, for example, by measuring the association rate constant (kA) and dissociation rate constant (kD) of an antibody and an antigen at equilibrium.
[0050] The term "binding avidity" refers to the combined strength of interaction of multiple binding sites of an antibody with the same target. Thus, avidity is not the sum of binding, but the sum of the synergistic strength of binding affinities. What is required for avidity is the multivalency of an antibody or functional multimer to one target (antigen), multiple accessible epitopes on one soluble target, or multiple binding of an antibody to one epitope on various immobilized targets. Thus, such an antibody exhibits avid binding to its target.
[0051] In principle, complex binding is not different between affine and avidine binding.However, complex dissociation in the case of avidine binding depends on the simultaneous dissociation of all the binding sites involved.Therefore, the increase in binding strength by avidine binding (compared to affine binding) depends on dissociation kinetics / complex stability.Therefore, for example, monovalent binding is dissociated faster compared to multivalent binding.Enrichment of multivalent binding over a long period of time by the method of the present invention can be used to increase the sensitivity of the method.
[0052] An "isolated" antibody is an antibody that is separated from components of its natural environment. In certain embodiments, the antibody is purified to a purity of more than 95% or 99%, for example, as determined by electrophoresis (e.g., SDS-PAGE, isoelectric focusing (IEF), capillary electrophoresis) or chromatography (e.g., ion-exchange HPLC or reverse-phase HPLC). For a review of methods for assessing antibody purity, see, for example, Flatman, S. et al., J. Chromatogr. B 848 (2007) 79-87.
[0053] multispecific antibodies In the method according to the invention, the amount of one or more avid conjugated by-products of at least the heterodimer and at least the bispecific antibody is determined.
[0054] A multispecific antibody is a monoclonal antibody that has binding specificities for at least two different targets, i.e., antigens. In certain embodiments, one of the binding specificities is for a first antigen and the other is for a different second antigen. In certain embodiments, a multispecific antibody binds to two different epitopes of the same antigen.
[0055] Techniques for producing multispecific antibodies include, but are not limited to, recombinant co-expression of two immunoglobulin heavy-light chain pairs with different specificities (see Milstein, C. and Cuello, A.C., Nature 305 (1983) 537-540, WO 93 / 08829, and Traunecker, A. et al., EMBO J. 10 (1991) 3655-3659), and "knob-in-hole" engineering (see, e.g., U.S. Pat. No. 5,731,168). Multispecific antibodies can be created by engineering electrostatic steering effects to create antibody Fc heterodimeric molecules (WO 2009 / 089004) or by using leucine zippers to create bispecific antibodies (see, e.g., Kostelny, SA et al., J. Immunol. 148 (1992) 1547-1553).
[0056] The antibody may also be a multispecific antibody as described in WO 2009 / 080251, WO 2009 / 080252, WO 2009 / 080253, WO 2009 / 080254, WO 2010 / 112193, WO 2010 / 115589, WO 2010 / 136172, WO 2010 / 145792 or WO 2010 / 145793.
[0057] Bispecific antibodies are generally antibody molecules that specifically bind to two different, non-overlapping epitopes on the same antigen or to two epitopes on different antigens.
[0058] A variety of bispecific antibody formats are known.
[0059] Exemplary bispecific antibody formats in which the methods according to the invention may be used are as follows: - CrossMab format (=CrossMab): a multispecific IgG antibody comprising a first Fab fragment and a second Fab fragment, in which in the first Fab fragment a) only the CH1 and CL domains are replaced with each other (i.e. the light chain of the first Fab fragment comprises the VL and CH1 domains and the heavy chain of the first Fab fragment comprises the VH and CL domains); b) only the VH and VL domains are replaced with each other (i.e. the light chain of the first Fab fragment comprises the VH and CL domains and the heavy chain of the first Fab fragment comprises the VL and CH1 domains); or c) the CH1 and CL domains are replaced with each other and the VH and VL domains are replaced with each other (i.e., the light chain of the first Fab fragment comprises the VH and CH1 domains and the heavy chain of the first Fab fragment comprises the VL and CL domains); and the second Fab fragment comprises a light chain comprising a VL domain and a CL domain, and a heavy chain comprising a VH domain and a CH1 domain; A CrossMab may comprise a first heavy chain comprising a CH3 domain and a second heavy chain comprising a CH3 domain, where both CH3 domains are as described in, for example, WO 96 / 27011, WO 98 / 050431, EP1870459, WO 2007 / 110205, WO 2007 / 147901, WO 2009 / 089004, WO 2010 / 129304, WO 201 ... To support heterodimerization of the first heavy chain and the modified second heavy chain, the first heavy chain and the modified second heavy chain have been engineered to be complementary by amino acid substitutions in each other, as disclosed in WO 2011 / 90754, WO 2011 / 143545, WO 2012 / 058768, WO 2013 / 157954, or WO 2013 / 096291 (herein incorporated by reference). - one-armed single-chain format (= one-armed single-chain antibody): an antibody comprising a first binding site which specifically binds to a first epitope or antigen and a second binding site which specifically binds to a second epitope or antigen, the individual chains being as follows: - Light chain (variable light domain + constant light kappa domain) - Light / heavy chain combination (variable light domain + light constant domain + peptide linker + variable heavy domain + CH1 + hinge + CH2 + CH3 with knob mutation) - heavy chain (variable heavy domain + CH1 + hinge + CH2 + CH3 with hole mutation); - T cell bispecific format (TCB format): a multispecific IgG antibody, a) a first and a second Fab fragment, each of which specifically binds to a first antigen; b) one domain-swapped Fab fragment which specifically binds to a second antigen and in which the CH1 and CL domains are replaced by each other; c) comprises an Fc region comprising a first heavy chain Fc-region polypeptide and a second heavy chain Fc-region polypeptide; the C-terminus of the CH1 domain of the first Fab fragment is connected to the N-terminus of one of the heavy chain Fc region polypeptides, and the C-terminus of the CL domain of the domain-exchanged Fab fragment is connected to the N-terminus of the other heavy chain Fc region polypeptide; and the C-terminus of the CH1 domain of the second Fab fragment is connected to the N-terminus of the VH domain of the first Fab fragment or the N-terminus of the VH domain of a domain-swapped Fab fragment; A multispecific IgG antibody, wherein the first or second antigen is human CD3; or a) a first and a second Fab fragment, each of which specifically binds to a first antigen; b) one domain-swapped Fab fragment which specifically binds to a second antigen and in which the VH and VL domains are replaced by each other; c) comprises an Fc region comprising a first heavy chain Fc-region polypeptide and a second heavy chain Fc-region polypeptide; the C-terminus of the CH1 domain of the first Fab fragment is connected to the N-terminus of one of the heavy chain Fc region polypeptides, and the C-terminus of the CH1 domain of the domain-exchanged Fab fragment is connected to the N-terminus of the other heavy chain Fc region polypeptide; and the C-terminus of the CH1 domain of the second Fab fragment is connected to the N-terminus of the VH domain of the first Fab fragment or the N-terminus of the VL domain of a domain-swapped Fab fragment; A multispecific IgG antibody, wherein the first or second antigen is human CD3; - full-length antibodies with domain swapping and an additional heavy chain C-terminal binding site (2+1 format): multispecific IgG antibodies, a) a full-length antibody comprising two pairs of full-length antibody light chains and full-length antibody heavy chains, wherein a binding site formed by each pair of full-length heavy chains and full-length light chains specifically binds to a first antigen; and b) one additional Fab fragment fused to the C-terminus of one heavy chain of the full-length antibody, the binding site of the additional Fab fragment specifically binding to a second antigen; a multispecific IgG antibody, in which the additional Fab fragment that specifically binds to the second antigen i) comprises a domain crossover such that a) the light chain variable domain (VL) and the heavy chain variable domain (VH) are replaced by each other, or b) the light chain constant domain (CL) and the heavy chain constant domain (CH1) are replaced by each other, or ii) is a single chain Fab fragment; - Two-armed single chain format (= 2-armed single chain antibody): an antibody comprising a first binding site that specifically binds to a first epitope or antigen and a second binding site that specifically binds to a second epitope or antigen, the individual chains being: - light / heavy chain combination 1 (variable light domain + light constant domain + peptide linker + variable heavy domain + CH1 + hinge + CH2 + CH3 with hole mutation); - light / heavy chain combination 2 (variable light domain + light constant domain + peptide linker + variable heavy domain + CH1 + hinge + CH2 + CH3 with knob mutation); - General light chain bispecific format (= general light chain bispecific antibody): an antibody comprising a first binding site that specifically binds to a first epitope or antigen and a second binding site that specifically binds to a second epitope or antigen, wherein the individual chains are as follows: - Light chain (variable light domain + constant light domain) - Heavy Chain 1 (VH domain + CH1 + hinge + CH2 + CH3 with hole mutation) - Heavy chain 2 (variable heavy domain + CH1 + hinge + CH2 + CH3 with knob mutation).
[0060] The term "TCB" as used herein refers to a T cell bispecific antibody. Such antibodies may have a format, for example, as described in WO 2013 / 026831. These molecules may simultaneously bind to CD3 (first specificity) on T cells and to an antigen (second specificity) on a target (e.g., tumor) cell, thereby inducing the killing of the target cell. TCBs are trivalent bispecific antibodies consisting of four polypeptides or polypeptide chains, one light chain that is a full-length light chain, an additional light chain that is a domain-exchanged full-length light chain, one heavy chain that is a full-length heavy chain, and an additional heavy chain that is an extended heavy chain containing an additional domain-exchanged heavy chain or light chain Fab fragment.
[0061] The term "domain crossover" as used herein refers to the deviation of the domain sequences from that of the native antibody in that in a pair of an antibody heavy chain VH-CH1 fragment and its corresponding cognate antibody light chain, i.e., in the antibody Fab (fragment-antigen binding), at least one heavy chain domain is replaced by its corresponding light chain domain, and vice versa. There are three general types of domain crossovers: (i) crossovers of CH1 and CL domains, where the domain crossover in the light chain results in a VL-CH1 domain sequence and the domain crossover in the heavy chain fragment results in a VH-CL domain sequence (or a full-length antibody heavy chain having a VH-CL-hinge-CH2-CH3 domain sequence); (ii) domain crossovers of VH and VL domains, where the domain crossover in the light chain results in a VH-CL domain sequence and the domain crossover in the heavy chain fragment results in a VL-CH1 domain sequence; and (iii) domain crossovers of a complete light chain (VL-CL) and a complete VH-CH1 heavy chain fragment ("Fab crossover"), where the domain crossover results in a light chain with a VH-CH1 domain sequence and the domain crossover results in a heavy chain fragment with a VL-CL domain sequence (all domain sequences listed above are in the N-terminal to C-terminal direction).
[0062] As used herein, the term "replaced with each other" with respect to corresponding heavy and light chain domains refers to the domain crossover described above. Thus, when CH1 and CL domains are "replaced with each other", this term refers to the domain crossover described under item (i) and the resulting heavy and light chain domain sequences. Thus, when VH and VL are "replaced with each other", this term refers to the domain crossover described under item (ii), and when CH1 and CL domains are "replaced with each other" and VH and VL domains are "replaced with each other", this term refers to the domain crossover described under item (iii). Bispecific antibodies comprising domain crossovers have been reported, for example, in WO 2009 / 080251, WO 2009 / 080252, WO 2009 / 080253, WO 2009 / 080254, and Schaefer, W., et al, Proc. Natl. Acad. Sci USA 108 (2011) 11187-11192. Such antibodies are generally referred to as CrossMab.
[0063] In certain embodiments, the multispecific or bispecific antibody is in CrossMab-format.
[0064] In certain embodiments, the multispecific or bispecific antibody is in TCB-format.
[0065] In certain embodiments, the multispecific or bispecific antibody is in a 2+1-format.
[0066] In certain embodiments, the multispecific or bispecific antibody is a single chain antibody.
[0067] In certain embodiments, the multispecific or bispecific antibody is a two-arm single chain antibody.
[0068] In certain embodiments, the multispecific or bispecific antibody is a generic light chain antibody.
[0069] Heterodimerization There are several approaches for CH3 modification to effect heterodimerization, which are fully described, for example, in WO 96 / 27011, WO 98 / 050431, EP 1 870459, WO 2007 / 110205, WO 2007 / 147901, WO 2009 / 089004, WO 2010 / 129304, WO 2011 / 90754, WO 2011 / 143545, WO 2012058768, WO 2013157954, WO 2013096291. Typically, in all such approaches, both the first and second CH3 domains are complementarily engineered such that each CH3 domain (or the heavy chain containing it) can no longer form homodimers with itself, but is forced to heterodimerize with the other complementarily engineered CH3 domain (so that the first and second CH3 domains heterodimerize and no homodimers are formed between the two first or two second CH3 domains). These different approaches for improving heavy chain heterodimerization are contemplated as different options in combination with heavy-light chain modifications in the multispecific antibodies according to the invention (VH and VL exchanges / substitutions in one binding arm, as well as introduction of substitutions of charged amino acids with opposite charges at the CH1 / CL interface) that reduce light chain mispairing of Bence-Jones type side products.
[0070] Outlined below are exemplary mutations in the CH3 domain that have been introduced to promote the formation of heterodimeric Fc regions, e.g., for the production of multispecific or bispecific antibodies.
[0071] Examples of such mutations are so-called "knob-into-hole" substitutions (e.g., WO 96 / 027011; Ridgway, JB et al., Protein Eng. 9 (1996) 617-621; Merchant, AM et al., Nat. Biotechnol. 16 (1998) 677-681; WO 98 / 050431; U.S. Patent No. 7,695,936 and U.S. Patent Application Publication No. 2003 / 0078385). The following knob and hole substitutions in the individual polypeptide chains of the Fc region of IgG antibodies of subclass IgG1 have been shown to increase heterodimer formation: 1) Y407T in one chain and T366Y in the other; 2) Y407A in one chain and T366W in the other; 3) F405A in one chain and T394W in the other; 4) F405W in one chain and T394S in the other; 5) Y407T in one chain and T366Y in the other; 6) T366Y and F405A in one chain and T394W and Y407T in the other; 7) T 366W and F405W and T394S and Y407A in the other chain; 8) F405W and Y407A in one chain and T366W and T394S in the other chain; and 9) T366W in one heavy chain Fc region and T366S, L368A and Y407V in the other respective heavy chain Fc region, the last listed being particularly suitable and therefore the subject of a preferred embodiment. Furthermore, substitutions that allow the formation of new disulfide bridges between the two Fc region polypeptide chains promote the formation of heterodimers (see, for example, Merchant, AM et al., Nature Biotech. 16 (1998) 677-681; Atwell, S. et al., J. Mol. Biol. 270 (1997) 26-35; US Patent Application Publication No. 2003 / 0078385).The following substitutions, which result in appropriately spaced cysteine residues for the formation of new intrachain disulfide bonds in the individual polypeptide chains of the Fc region of IgG antibodies of subclass IgG1, have been found to increase heterodimer formation: in a preferred embodiment, Y349C in one heavy chain Fc region and S354C in the respective other heavy chain Fc region; Y349C in one chain and E356C in the other chain; Y349C in one chain and E357C in the other chain; L351C in one chain and S354C in the other chain; T394C in one chain and E397C in the other chain; or D399C in one chain and K392C in the other chain.
[0072] Further examples of heterodimerization promoting amino acid changes are so-called "charge pair substitutions" (see, for example, WO 2009 / 089004). The following charge pair substitutions in the individual polypeptide chains of the Fc region of an IgG antibody of subclass IgG1 have been shown to increase heterodimer formation: 1) K409D or K409E on one strand and D399K or D399R on the other; 2) K392D or K392E on one strand and D399K or D399R on the other; 3) K439D or K439E on one strand and E356K or E356R on the other; 4) K370D or K370E on one strand and E357K or E357R on the other; 5) K409D and K360D on one strand plus D399K and E356K on the other; 6) K409D and K370D on one strand plus D399K and E357K on the other; 7) K409D and K392D on one strand. 9) K409D and K392D on one chain and D399K and E356K on the other chain; 10) K409D and K392D on one chain and D399K and D357K on the other chain; 11) K409D and K370D on one chain and D399K and D357K on the other chain; 12) D399K on one chain and K409D and K360D on the other chain; and 13) K409D and K439D on one chain and D399K and E356K on the other.
[0073] In a preferred embodiment of all aspects and embodiments, the first Fc region polypeptide comprises the mutations Y349C, T366S, L368A and Y407V ("hole") and the second Fc region polypeptide comprises the mutations S354C and T366W ("knob").
[0074] Other techniques for CH3 modification to effect heterodimerization are contemplated as alternative methods for use in the methods of the present invention and are described, for example, in WO 96 / 27011, WO 98 / 050431, EP 1 870459, WO 2007 / 110205, WO 2007 / 147901, WO 2009 / 089004, WO 2010 / 129304, WO 2011 / 90754, WO 2011 / 143545, WO 2012 / 058768, WO 2013 / 157954, WO 2013 / 096291.
[0075] Alternatively, the heterodimerization approach described in WO2013 / 157953 may be used. In certain embodiments, the first CH3 domain comprises an amino acid T366K mutation, and the second CH3 domain polypeptide comprises an amino acid L351D mutation. In certain embodiments, the first CH3 domain comprises an additional amino acid L351K mutation. In certain embodiments, the second CH3 domain comprises an additional amino acid mutation selected from Y349E, Y349D and L368E (preferably L368E).
[0076] Alternatively, the heterodimerization approach described in WO 2012 / 058768 may be used. In certain embodiments, the first CH3 domain comprises amino acid L351Y, Y407A mutations, and the second CH3 domain comprises amino acid T366A, K409F mutations. In certain embodiments, the second CH3 domain comprises an additional amino acid mutation at position T411, D399, S400, F405, N390 or K392, e.g. selected from a) T411N, T411R, T411Q, T411K, T411D, T411E or T411W, b) D399R, D399W, D399Y or D399K, cS400E, S400D, S400R or S400K, F405I, F405M, F405T, F405S, F405V or F405W, N390R, N390K or N390D, K392V, K392M, K392R, K392L, K392F or K392E. In certain embodiments, the first CH3 domain comprises amino acid L351Y, Y407A mutations, and the second CH3 domain comprises amino acid T366V, K409F mutations. In certain embodiments, the first CH3 domain comprises amino acid Y407A mutations, and the second CH3 domain comprises amino acid T366A, K409F mutations. In certain embodiments, the second CH3 domain comprises additional amino acid K392E, T411E, D399R and S400R mutations.
[0077] In certain embodiments, the heterodimerization approach described in WO 2011 / 143545 may instead be used, for example with amino acid modifications at positions selected from the group consisting of 368 and 409.
[0078] The heterodimerization approach described in WO 2011 / 090762, which also uses the knobs-into-holes technique described above, may be used instead. In certain embodiments, the first CH3 domain comprises an amino acid T366W mutation and the second CH3 domain comprises an amino acid Y407A mutation. In certain embodiments, the first CH3 domain comprises an amino acid T366Y mutation and the second CH3 domain comprises an amino acid Y407T mutation.
[0079] Alternatively, the heterodimerization approach described in WO2009 / 089004 may be used.In certain embodiments, the first CH3 domain comprises an amino acid substitution with a negatively charged amino acid at K392 or N392 (e.g., glutamic acid (E) or aspartic acid (D), preferably K392D or N392D), and the second CH3 domain comprises an amino acid substitution with a positively charged amino acid at D399, E356, D356 or E357 (e.g., lysine (K) or arginine (R), preferably D399K, E356K, D356K or E357K), and in a preferred embodiment, comprises an amino acid substitution with D399K and E356K. In certain embodiments, the first CH3 domain further comprises an amino acid substitution at K409 or R409 with a negatively charged amino acid (e.g., glutamic acid (E) or aspartic acid (D), preferably K409D or R409D). In certain embodiments, the first CH3 domain further or alternatively comprises an amino acid substitution at K439 and / or K370 with a negatively charged amino acid (e.g., glutamic acid (E) or aspartic acid (D)).
[0080] Alternatively, the heterodimerization approach described in WO 2007 / 147901 may be used. In certain embodiments, the first CH3 domain comprises the amino acid mutations K253E, D282K and K322D, and the second CH3 domain comprises the amino acid mutations D239K, E240K and K292D.
[0081] In certain embodiments, the heterodimerization approach described in WO 2007 / 110205 may be used instead.
[0082] Recombinant methods and compositions Antibodies may be produced using recombinant methods and compositions, e.g., as described in U.S. Pat. No. 4,816,567. In certain embodiments, an isolated nucleic acid encoding the antibody is provided. Such a nucleic acid may encode an amino acid sequence comprising the VL of the antibody and / or an amino acid sequence comprising the VH of the antibody (e.g., the light and / or heavy chains of the antibody). In certain embodiments, one or more plasmids (e.g., expression plasmids) comprising such a nucleic acid are provided. In certain embodiments, a host cell comprising such a nucleic acid is provided. In certain embodiments, the host cell comprises (e.g., transformed): (1) a plasmid comprising a nucleic acid encoding an amino acid sequence comprising the VL of the antibody and an amino acid sequence comprising the VH of the antibody, or (2) a first plasmid comprising a nucleic acid encoding an amino acid sequence comprising the VL of the antibody and a second plasmid comprising a nucleic acid encoding an amino acid sequence comprising the VH of the antibody. In certain embodiments, the host cell is a eukaryotic cell, e.g., a Chinese Hamster Ovary (CHO) cell or a lymphoid cell (e.g., a Y0, NS0, Sp2 / 0 cell). In certain embodiments, the method according to the invention further comprises a step of producing the antibody to be tested therein, the method comprising culturing a host cell comprising an antibody-encoding nucleic acid as provided above under conditions suitable for expression of the antibody, recovering the antibody from the host cell (or the host cell culture medium), and subjecting the antibody to a method according to the invention for measuring or determining the content of antibody-associated avidin-conjugated by-products.
[0083] For recombinant production of an antibody using methods such as those outlined above, nucleic acid encoding the antibody, e.g., as described above, is isolated and inserted into one or more plasmids for further cloning and / or expression in a host cell. Such nucleic acid can be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes capable of specifically binding to genes encoding the variant Fc region polypeptide or the heavy and light chains of the antibody).
[0084] Suitable host cells for cloning or expressing the antibody-encoding plasmids include eukaryotic cells.
[0085] For example, eukaryotic microbes such as filamentous fungi or yeast are suitable cloning or expression hosts for antibody-encoding plasmids, including fungal and yeast strains in which the glycosylation pathway has been "humanized," resulting in the production of antibodies with partial or fully human glycosylation patterns. See Gerngross, TU, Nat. Biotech. 22 (2004) 1409-1414; and Li, H. et al., Nat. Biotech. 24 (2006) 210-215.
[0086] For example, mammalian cell lines that are adapted to grow in suspension may be useful. Other examples of useful mammalian host cell lines are monkey kidney CV1 line (COS-7) transformed by SV40; human embryonic kidney lines (e.g., HEK293 or 293 cells, described in Graham, FL et al., J. Gen Virol. 36 (1977) 59-74; baby hamster kidney cells (BHK); mouse Sertoli cells (e.g., TM4 cells, described in Mather, JP, Biol. Reprod. 23 (1980) 243-252); monkey kidney cells (CV1); African green monkey kidney cells (VERO-76); human cervical carcinoma cells (HELA); canine kidney cells (MDCK)p; buffalo rat hepatocytes (BRL 3A); human lung cells (W138); human hepatocytes (Hep G2); mouse mammary tumor (MMT 060562); TRI cells, described in, e.g., Mather, JP et al., Annals NYAcad. Sci. 383 (1982) 44-68; MRC Other useful mammalian host cell lines include DHFR 5 cells; and FS4 cells. -Chinese hamster ovary (CHO) cells, including CHO cells (Urlaub, G. et al., Proc. Natl. Acad. Sci. USA 77 (1980) 4216-4220), and myeloma cell lines, e.g., Y0, NS0 and Sp2 / 0. For a review of certain mammalian host cell lines suitable for antibody production, see, e.g., Yazaki, P. and Wu, AM, Methods in Molecular Biology, Vol. 248, Lo, BKC (ed.), Humana Press, Totowa, NJ (2004), pp. 255-268. In a preferred embodiment, the host cell is a CHO or HEK cell.
[0087] Cutting-edge surface plasmon resonance The kinetic binding parameters of the antibodies to the respective antigens can be studied by surface plasmon resonance using a BIAcore instrument (GE Healthcare Biosciences AB, Uppsala, Sweden).
[0088] Briefly, for affinity determination, the target / antigen of a capture agent, e.g., an antibody, is covalently immobilized on a chip, e.g., a CM5 chip, via amine coupling for presentation to the respective antibody to be captured and analyzed.
[0089] For example, approximately 2,000-12,000 response units (RU) of a 10-30 μg / ml target solution are coupled onto all flow cells of a CM5 sensor chip in a BIAcore T200 instrument at pH 5.0 with a flow rate of 10-30 μl / min by using an amine coupling kit supplied by GE Healthcare.
[0090] Binding is measured in HBS buffer (HBS-P (10 mM HEPES, 150 mM NaCl, 0.005% Tween 20, pH 7.4), or HBS-EP+ (0.01 M HEPES, 0.15 M NaCl, 3 mM EDTA, 0.05% v / v surfactant PS20, pH 7.4), or HBS-ET (10 mM HEPES pH 7.4, 150 mM NaCl, 3 mM EDTA, 0.005% w / v Tween 20)) at 25°C (or alternatively at different temperatures ranging from 4°C to 45°C).
[0091] As a result, antibodies are injected for 30 s at concentrations ranging from 10 nM to 1 µM and allowed to bind to the active flow cells (e.g., 2, 3 and 4 or 2 and 3), with the other flow cells serving as reference flow cells.
[0092] The corresponding antigen (secondary target) is then added at various concentrations in solution, depending on the affinity of the antibody, for example 144 nM, 48 nM, 16 nM, 5.33 nM, 1.78 nM, 0.59 nM, 0.20 nM and 0 nM.
[0093] Binding is measured by antigen injection.
[0094] Dissociation is measured by washing the surface of the chip with an analyte-free buffer.
[0095] K D Values are estimated using a 1:1 Langmuir binding model using the manufacturer's software and instructions. Negative control data (e.g., buffer curve) are subtracted from sample curves to correct for system-specific baseline drift and to reduce noise signals.
[0096] Examples and exemplary embodiments of the method according to the invention Methods according to the invention using 2+1 format antibodies The method according to the present invention is illustrated in the first example below using a bispecific anti-Abeta / transferrin receptor antibody. This is presented merely to illustrate the invention and should not be construed as limiting in any way. The true scope of the invention is set forth in the appended claims.
[0097] The bispecific anti-Abeta / transferrin receptor antibody used in this example is formed from a Y-shaped full-length antibody containing two binding sites that specifically bind to human Abeta protein and one additional monospecific Fab that specifically binds to human transferrin receptor fused via a peptide linker to one of the C-terminus of the heavy chain of the Abeta antibody.
[0098] In order to properly shuttling the blood-brain barrier, bispecific anti-Abeta / transferrin receptor antibodies must be monovalent for the human transferrin receptor, as bivalent binding greatly reduces or eliminates shuttling (see, e.g., WO 2016 / 207245, incorporated herein by reference).
[0099] Since the bispecific anti-Abeta / transferrin receptor antibody comprises two different heavy chains, the CH3 domains of the heavy chains have been modified according to a knob-into-hole heterodimerization strategy (see Merchant et al., supra): the heavy chain conjugated to the further Fab contains a knob mutation and the other, unextended heavy chain contains a hole mutation.
[0100] For this exemplary antibody, the antibody-associated avid binding by-product detected by the method according to the invention is a homodimer containing two heavy chains linked to an additional Fab, i.e. an antibody containing two binding sites for Abeta protein and two binding sites for the human transferrin receptor. A correctly assembled bispecific antibody contains two binding sites for the human Abeta protein, as outlined above, but only one binding site for the human transferrin receptor. This antibody-associated avid binding by-product must be detected because it is unable to shuttle properly across the blood-brain barrier due to bivalent binding to the human transferrin receptor.
[0101] According to the method of the present invention, the by-product to be detected is an antigen with an increased number of binding sites compared to a correctly assembled antibody, i.e., in this example, two instead of one, immobilized on the surface of the SPR chip. In this example, the immobilization was indirect. The antigen, i.e., the human transferrin receptor, was linked to a biotin tag and captured on the surface of a streptavidin-modified CAP chip (Cytiva) after hybridization of single-stranded DNA precoated on the chip with its streptavidin-carrying complementary strand (see FIG. 1).
[0102] In this example, immobilization was performed up to about 2250 RU.
[0103] A sample containing a correctly assembled bispecific anti-Abeta / transferrin receptor antibody was applied to the surface of the immobilized human transferrin receptor. The correctly assembled antibody specifically binds to the immobilized human transferrin receptor, thereby becoming bound to the surface of the chip. This generates an SPR signal. To dissociate the antibody from the surface of the chip, an aqueous buffer solution was applied to the chip that did not contain the bispecific antibody or any other compounds that bind to the human transferrin receptor. The decay of the SPR (binding) signal was recorded and used as a baseline value.
[0104] To determine the presence / amount of antibody-related by-products with avidin binding to human transferrin receptor in the method according to the invention, the surface of an immobilized transferrin receptor chip was prepared as outlined above. To this surface with immobilized human transferrin receptor, a sample containing correctly assembled antibody as well as homodimeric antibody-related avidin binding by-products was applied. The antibody and by-products bind to the immobilized human transferrin receptor, thereby becoming bound to the surface of the chip.
[0105] At low concentrations of by-products, the weight difference between properly assembled antibody and antibody-associated homodimeric by-products is so small that it results in virtually no detectable difference in the SPR signal compared to the binding of properly assembled antibody alone after the sample is applied to the surface of the chip.
[0106] However, antibody-associated homodimeric by-products due to bivalency and avidin binding to the immobilized transferrin receptor accumulate on the surface of the chip during the loading step because they displace properly assembled antibodies that are only monovalent and have only affine binding to the immobilized transferrin receptor, and their accumulation is achieved by the fact that the complexes of the avidin binding by-products with the transferrin receptor have higher complex stability than the complexes of properly assembled affin binding antibodies.
[0107] To dissociate the correctly assembled antibody as well as the avidin-binding by-product from the surface of the chip, a buffered aqueous solution that did not contain the antibody or any other compounds that bind to the human transferrin receptor was applied to the chip. The decay of the SPR (binding) signal was recorded, which is the signal value.
[0108] At defined time points after the onset of dissociation, the difference between the signal value and the baseline value is determined, this difference being called the residual binding.
[0109] Residual binding depends on the amount of antibody-associated homodimeric avidin-conjugated by-product in the sample.
[0110] An exemplary SPR sensorgram is shown in FIG. 2 (RS=correctly assembled antibody; k / k=knob-knob-homodimer).
[0111] Various standards were prepared by spiking known amounts of antibody-associated homodimer abiding by-products into isolated, correctly assembled antibody samples, and a calibration curve was generated. The calibration curve was linear up to a content of at least 5% (w / w) antibody-associated homodimer abiding by-products (see FIG. 3), with a R 2 The value is 0.9785.
[0112] Thus, the determined residual binding can / does directly correlate with the amount of antibody-associated homodimeric avidin-conjugated by-product in the applied sample.
[0113] Application of the method according to the invention makes it possible to quantify small amounts of antibody-related homodimeric avid-linked by-products in a sample, in particular amounts well below 2% of antibody-related avid-linked by-products.
[0114] Conditions for this example for antibodies in 2+1 format: Antigen immobilization level = 2250RU · Antibody concentration=100nM Sample flow rate = 30 μl / min Bonding time = 180 seconds Dissociation time = 600 seconds · Temperature=25℃ · Buffer composition = HBS-EP+
[0115] It should be pointed out that in addition to sequential determination / recording of reference and signal values, this can also be done in parallel using different flow cells of the SPR chip or different SPR devices.
[0116] However, it is necessary to take into account the criteria applied to the blank cells, i.e. the subtraction of the results obtained with the blank cells. This is done to eliminate the influence of any independent / non-specific binding.
[0117] Methods according to the invention using TCB format antibodies This is a second example of the method according to the present invention. The method according to the present invention is exemplified below using a bispecific anti-CD3 / antigen-2 antibody. This is presented merely to illustrate the present invention and should not be construed as limiting in any way. The true scope of the present invention is set forth in the appended claims.
[0118] In this example, a bispecific anti-CD3 / antigen-2 antibody is used. This antibody is based on a Y-shaped full-length antibody that contains two Fabs that (specifically) bind to antigen-2 and one additional monospecific Fab that (specifically) binds to CD3, inserted between one of the Fabs of the full-length antibody that (specifically) binds to antigen-2 and the hinge region. This antibody format is called TCB (T-cell activating bispecific antibody format).
[0119] TCBs bind to T cells through their CD3 binding sites, which (specifically) bind to the T cell receptor (TCR) complex on the surface of T cells. In the case of TCBs, homodimeric by-products containing two CD3 binding sites pose a significant safety risk due to their ability to activate T cells in the absence of target cells by TCR dimerization. This non-specific (also known as target cell-independent) T cell activation may induce cytokine secretion or trigger an unwanted immune response in patients. Non-specific T cell activation by antibody-related homodimeric avidin-binding by-products containing two CD3 binding sites is an unwanted activity and is different from the intended T cell activation by a correctly assembled TCB. Therefore, it is important to determine the amount of antibody-related homodimeric avidin-binding by-products containing two CD3 binding sites.
[0120] As the bispecific anti-CD3 / antigen-2 antibody contains two different heavy chains, the CH3 domains of the heavy chains have been modified according to the knob-into-hole heterodimerization strategy (see Merchant et al., supra): the extended heavy chain into which an additional Fab that (specifically) binds to CD3 has been inserted contains a knob mutation, whereas the other non-extended heavy chain contains a hole mutation.
[0121] In this exemplary antibody, the antibody-associated avidin-binding by-product detected by the method according to the invention is a homodimer containing two heavy chains, each with an inserted Fab, i.e. a compound containing two binding sites for CD3. A correctly assembled bispecific antibody contains only one binding site for CD3, as outlined above. This by-product must be detected, since it may result in non-specific T cell activation due to bivalent binding to CD3.
[0122] The method according to the invention allows the by-product to be detected, compared to a correctly assembled antibody, where an increased number of antigens containing binding sites, i.e. in this case two instead of one, are immobilized on the surface of the SPR chip. In this example, the immobilization was direct immobilization. The antigen, i.e. CD3, is immobilized on the surface of the chip by amine coupling according to the manufacturer's instructions.
[0123] CD3 was immobilized to approximately 6900 RU on a CM5 chip using amine coupling according to the manufacturer's instructions.
[0124] A sample containing the correctly assembled bispecific antibody was applied to the surface with immobilized CD3. The correctly assembled bispecific antibody binds to the immobilized CD3 and thereby becomes bound to the surface of the chip. This generates an SPR signal. To dissociate the bispecific antibody from the surface of the chip, a buffered aqueous solution that does not contain the bispecific antibody or any other compounds that bind to CD3 was applied to the chip. The decay of the SPR (binding) signal was recorded and this was taken as the baseline value.
[0125] In the second part of the method, the surface of an immobilized CD3 chip is prepared as outlined above. To this surface with immobilized CD3 is applied a sample containing the correctly assembled bispecific antibody as well as the bispecific antibody-associated homodimeric avidin-conjugated by-product. Both bind to the immobilized CD3, thereby becoming bound to the surface of the chip.
[0126] The weight difference between properly assembled antibody and the antibody-associated homodimeric abido-conjugated by-product is so small that it results in virtually no detectable difference in the SPR signal compared to properly assembled antibody binding alone.
[0127] However, the homodimeric by-products due to bivalency and avidin binding to immobilized CD3 accumulate on the surface of the chip. This displaces the correctly assembled bispecific antibody, which is only monovalent to immobilized CD3 and has only affine binding during the loading step. The avidin-linked bispecific antibody-associated by-product complex has higher complex stability compared to the correctly assembled affin-linked bispecific antibody complex, allowing accumulation during the loading step.
[0128] To dissociate the correctly assembled bispecific antibody and avidin-binding by-products from the surface of the chip, a buffered aqueous solution that did not contain antibodies or any other compounds that bind to CD3 was applied to the chip. The decay of the SPR (binding) signal was recorded, which is the signal value.
[0129] At defined time points after the onset of dissociation, the difference between the signal value and the baseline value is determined, this difference being called the residual binding.
[0130] Residual binding depends on the amount of bispecific antibody-associated homodimeric avid-conjugated by-product in the sample.
[0131] Two different approaches to determine the standard curve have been used. In the first (top curve in FIG. 4), the addition of the avidin-conjugated by-product (knob-knob homodimer; KK) was performed to the isolated bispecific antibody, i.e., to a preparation that does not contain detectable amounts of the avidin-conjugated by-product (R 2In the second (lower curve in Figure 4), the avidino-conjugated by-product was spiked in a reference material (with an R2 value of 0.9998) that already contained detectable amounts of the avidino-conjugated by-product. In this case, it can be seen that a calibration curve can also be established. The calibration curve is linear up to at least 2% (w / w) of the homodimeric by-product.
[0132] The determined residual binding can therefore be correlated with the amount of bispecific antibody homodimer avid-conjugated by-product in the applied sample.
[0133] Application of the method according to the invention makes it possible to quantify small amounts of homodimer by-products in a sample.
[0134] Summary of conditions for this example for antibodies in TCB format: Antigen immobilization level = 6900RU · Antibody concentration=100nM Sample flow rate = 20 μl / min Bonding time = 480 seconds Dissociation time = 1200 seconds · Temperature=37℃ · Buffer composition = HBS-P+
[0135] Methods according to the invention using CrossMab format antibodies This is a further example of the method according to the present invention. In this example, the method according to the present invention is illustrated using a bispecific antibody that specifically binds to two different CD antigens. This is presented merely to illustrate the present invention and should not be construed as limiting in any way. The true scope of the present invention is set forth in the appended claims.
[0136] The bispecific antibodies used in this example are Y-shaped full-length antibodies that contain one binding site that specifically binds to a first CD antigen and one binding site that specifically binds to a second, different CD antigen. Bispecific antibodies are in the so-called CrossMab format (see above).
[0137] Since bispecific antibodies contain two different heavy chains, the CH3 domains of the heavy chains are modified according to the knob-into-hole heterodimerization strategy (see Merchant et al., supra): the heavy chain that binds the first CD antigen contains a knob mutation and the other heavy chain contains a hole mutation.
[0138] For this exemplary antibody, the antibody-associated avidin-conjugated by-product detected by the method according to the invention is a homodimer containing two heavy chains that both bind to a first CD antigen. A correctly assembled bispecific antibody contains only one binding site for each CD antigen.
[0139] Bivalent conjugates to the first CD antigen must be detected due to the bivalent binding to the first CD antigen, where harmful, i.e. toxic, side effects may occur, for example, by target-independent T cell activation. Thus, these antibody-associated homodimeric avidin conjugated by-products require monitoring and (accurate) quantification, as they may represent a potential safety risk due to target-independent activation of T cells.
[0140] According to the method of the invention, an antigen is immobilized on the surface of an SPR chip, the by-product of which contains a higher number of binding sites for said antigen compared to the correctly assembled antibody (i.e. two instead of one). In this example, the immobilization of the first CD antigen was direct immobilization on the surface of the chip.
[0141] Immobilization of the first CD antigen was performed at above 2000 RU, however, it was found that it should not exceed 4000 RU.
[0142] A sample containing a correctly assembled antibody is applied to the surface with the immobilized first CD antigen. The correctly assembled antibody specifically binds to the immobilized CD antigen, thereby becoming bound to the surface of the chip. This generates an SPR signal. To dissociate the antibody from the surface of the chip, an aqueous buffer solution is applied to the chip that does not contain the bispecific antibody or any other compound that binds to the first CD antigen. The decay of the SPR (binding) signal is recorded and used as a baseline value.
[0143] As outlined above, various possible by-products of increasing valency for the first CD antigen have also been applied to the chip (see Figure 5). As the avid linkages are more stable than the properly assembled bispecific antibody, it can be seen that all the avid linkage by-products associated with the antibody are retained on the surface, including (K) knob monomers (which spontaneously associate in solution to form homodimers (as confirmed by SEC)), (KK) knob-knob homodimers (covalent and non-covalent forms behave similarly), and solution containing various aggregates.
[0144] It can be seen that the isolated avid-conjugated by-product does not dissociate with a detectable off-rate (see FIG. 6), whereas a properly assembled bispecific antibody (bsmAb) does.
[0145] To highlight and more clearly exploit the difference in complex stability between monovalent and avidin-binding antibody forms, a long dissociation phase can be used. This allows correctly assembled heterodimeric affine-binding bispecific antibodies (monovalent first and second CD antigen binding) to dissociate from the surface of the chip. In contrast, all species with bivalent and multivalent avidin-binding interactions to the first CD antigen are retained. The SPR readout, i.e. "residual binding", can be determined after a long dissociation phase, for example about 1200 seconds after the start of dissociation.
[0146] The surface of the immobilized first CD antigen chip was prepared as outlined above. A sample containing one isolated knob heavy chain (monomeric by-product) as well as homodimeric by-product was applied to the surface. All antibodies bind (specifically) to the immobilized first CD antigen, thereby becoming bound to the surface of the chip (see Figures 6 and 7). Based on the analytical data, it is speculated that the monomeric knob by-product dimerizes in situ to form the homodimeric by-product.
[0147] The complex of bound homodimeric avid-binding by-product has a higher complex stability than the complex of correctly assembled heterodimeric affine-binding antibody, and therefore accumulation of this homodimeric avid-binding by-product occurs during the loading step.
[0148] To dissociate the correctly assembled antibody and homodimeric avid-binding by-product from the surface of the chip, a buffered aqueous solution that does not contain the antibody or any other compound that binds to the first CD antigen is applied to the chip. The decay of the SPR (binding) signal is recorded. It can be seen that significant residual binding can be determined for homodimeric avid-binding by-product (see Figure 6 and Figure 7).
[0149] In the second part of the method, a chip surface with immobilized first CD antigens is prepared as outlined above. To this surface with immobilized first CD antigens, a sample containing only correctly assembled antibodies, as well as a sample spiked with 1% (w / w) of various antibody-associated homodimeric avidin-conjugated by-products, are applied. All bind to the immobilized first CD antigens and thereby become bound to the surface of the chip.
[0150] The weight difference between the correctly assembled heterodimeric antibody and the homodimeric avid-conjugated by-product is too small to result in a detectable difference in the SPR signal.
[0151] Similarly, using other biochemical methods such as SEC, CE-SDS or HIC would not detect any difference since the molecular characteristics used for discrimination in these methods are the same. Only by the method according to the present invention can the discrimination by different kinetic binding characteristics be achieved. Since this difference exists in all heterodimeric antibody formats, the method according to the present invention can be applied to at least any such format for the determination of antibody-related homodimeric avidin binding by-products.
[0152] The homodimeric by-products, bivalent and avid-linked to the immobilized first CD antigen, accumulate on the surface of the chip. This displaces the correctly assembled but only affine-linked (only monovalent to the immobilized first CD antigen and therefore only affine-linked) bispecific antibody. The bound antibody-associated homodimeric avid-linked by-product complex has a higher complex stability than the correctly assembled heterodimeric affine-linked bispecific antibody complex. Thus, the accumulation of the by-products is possible.
[0153] To dissociate the correctly assembled heterodimeric affine-binding bispecific antibody as well as the antibody-associated homodimeric avidin-binding by-products from the surface of the chip, a buffered aqueous solution that does not contain the antibody or any other compound that binds to the first CD antigen was applied to the chip. The decay of the SPR (binding) signal was recorded, which is the signal value.
[0154] At a defined time point after the start of dissociation, the difference between the signal value and the baseline value can be / is determined. This difference is called residual binding.
[0155] This effect is shown in Figure 8, where 1% (w / w) avidin-conjugated by-product was added to isolated correctly assembled antibody (LS) (100 nM correctly assembled antibody plus 1 nM by-product).
[0156] The residual binding difference depends on the amount of homodimeric by-product in the sample.
[0157] All the different antibody associated bivalent and multivalent first CD antigen avid conjugated by-products are quantified together, ie, in total.
[0158] If isolated heterodimeric affine-binding bispecific antibodies are not available, they can be quantified by "calibration by standard addition". A defined homodimeric molecule (homodimeric avidin-binding by-product) is used as the by-product standard. After calculation, the "% value of the total highly active bivalent first CD antigen conjugates" is given as the "% value of the homodimeric standard equivalent".
[0159] At defined time points after the onset of dissociation, the difference between the signal value and the baseline value is determined, this difference being called the residual binding.
[0160] The residual binding difference depends on the amount of homodimeric avidin-conjugated by-product in the sample.
[0161] Various standards were prepared by spiking known amounts of homodimeric avidin-binding by-products into isolated, correctly assembled, heterodimeric affin-binding antibody samples, and a calibration curve was generated. The calibration curve is linear up to at least 2% (w / w) homodimeric by-product content (R 2 value 0.9997) (see FIG. 9).
[0162] The determined residual binding can therefore be related to the amount of homodimeric abidio-conjugated by-product in the sample.
[0163] Application of the method according to the invention makes it possible to quantify small amounts of homodimeric abiding by-products in a sample.
[0164] Conditions used in this example for antibodies in CrossMab format: Antigen immobilization level = 2000RU~4000RU · Antibody concentration=100nM Sample flow rate = 20 μl / min Bonding time = 480 seconds Dissociation time = 1200 seconds · Temperature=25℃ · Buffer composition = HBS-P+
[0165] General conditions of the process according to the invention: - an antigen immobilization amount of at least about 2000 RU, in a preferred embodiment in the range of 2000 RU to 8000 RU; - Loading time in the range of 180 seconds to 480 seconds, with a preferred embodiment of about 360 seconds - a concentration of correctly assembled antibodies in the sample in the range of 50 nM to 200 nM, in a preferred embodiment about 100 nM - a flow rate in the range of 10 μL / min to 30 μL / min, in a preferred embodiment a flow rate in the range of about 20 μL / min to about 30 μL / min - Residual binding may be determined at any time after dissociation has begun, in a preferred embodiment residual binding may be determined after at least 400 seconds, at least 480 seconds, or at least 1200 seconds. - Residual binding depends on the binding activity of the by-product, so there need not be any difference in off-rate between the correctly assembled antibody and the homodimeric by-product - Residual binding can be adjusted by flow rate and time
[0166] Specific embodiments of the present invention: 1. A method for determining avidin-binding by-products of a bispecific antibody in a sample containing a properly assembled bispecific antibody and one or more avidin-binding by-products of the bispecific antibody using surface plasmon resonance, comprising: A properly assembled bispecific antibody contains one or more binding sites for a first antigen and one or more binding sites for a second antigen, the avid-conjugated by-product of the bispecific antibody contains two or more, and many more, binding sites for the first antigen than the properly assembled bispecific antibody; The method comprises: i) applying a loading solution containing the correctly assembled bispecific antibody to an SPR surface on which a first antigen has been immobilized at at least 1000 RU to generate an SPR signal, and then applying a dissociation solution that does not contain a compound that binds to the first antigen to the SPR chip and recording the decay of the SPR signal; ii) applying a sample solution suspected of containing an avidin-binding by-product of the bispecific antibody to an SPR surface having a first antigen immobilized thereon at least 1000 RU to generate an SPR signal, and then applying a dissociation solution that does not contain the compound that binds to the first antigen to the SPR chip and recording the decay of the SPR signal; iii) determining the avidin-binding by-products of the bispecific antibody when the decay of the SPR signal determined in step ii) is slower than the decay of the SPR signal determined in step i); A method comprising: 2. The method of embodiment 1, wherein the first antigen is immobilized at at least 2000 RU. 3. The method of embodiment 1 or 2, wherein the first antigen is immobilized at 2000 RU or more and 8000 RU or less. 4. The method of any one of the preceding claims, wherein the application of the loading solution and / or sample is at a flow rate of 5 μL / min to 50 μL / min for at least 300 seconds. 5. The method of any one of the preceding claims, wherein the application of the loading solution and / or sample is at a flow rate of 5 μL / min to 50 μL / min for at least 400 seconds. 6. The method of any one of the preceding embodiments, wherein the application of the dissociation solution is at a flow rate of 5 μL / min to 50 μL / min for at least 600 seconds. 7. The method of any one of the preceding embodiments, wherein the application of the dissociation solution is at a flow rate of 5 μL / min to 50 μL / min for at least 1200 seconds. 8. The method according to any one of the preceding claims, wherein the loading solution and the sample are applied under the same conditions. 9. The method according to any one of embodiments 1 to 3 and 6 to 8, wherein the application of the dissociation solution in steps i) and ii) is under the same conditions. 10. The method of any one of embodiments 4 to 9, wherein the flow rate is between 15 μL / min and 35 μL / min. 11. The method according to any one of the preceding claims, wherein the determination in step iii) is based on an SPR signal determined at least 400 seconds after the start of application of the dissociation solution, and the SPR signal obtained with the loading solution at the start of application of the dissociation solution in steps i) and ii) is identical. 12. The method according to any one of embodiments 1 to 6 and 8 to 11, wherein the determination in step iii) is based on an SPR signal determined at a time point of at least 1200 seconds after the start of application of the dissociation solution, and the SPR signal obtained with the loading solution at the start of application of the dissociation solution in steps i) and ii) is made identical. 13.Antibodies i) a bispecific antibody in CrossMab format, or ii) a bispecific antibody in TCB format, or iii) The method according to any one of embodiments 1 to 12, wherein the antibody is a bispecific antibody in a 2+1 format. 14. The method of any one of embodiments 1 to 13, for determining the presence of antibody-related homodimeric avidin-binding by-products. 15. The method according to any one of the preceding embodiments, for quantifying the presence of antibody-related homodimeric abiding by-products.
[0167] Figures and Examples The following examples and figures are provided to aid the understanding of the present invention, the true scope of which is set forth in the appended claims. It is understood that modifications can be made in the procedures set forth without departing from the spirit or scope of the invention. [Brief description of the drawings]
[0168] [Figure 1]Schematic of the assay setup in which the human transferrin receptor is indirectly immobilized via a biotin tag on the surface of a streptavidin-modified CAP chip after hybridization of single-stranded DNA precoated on the chip with its streptavidin-loaded complementary strand. [Diagram 2] Decay of SPR signal during dissociation of isolated correctly associated antibody (lower curve; red) as well as a sample containing 20% avidinoconjugated by-products (upper curve; green) from the surface of the chip using an antibody-free aqueous buffer solution. The difference between the upper and lower signal values is the residual binding. [Diagram 3] Calibration curve for the determination of avid conjugation by-products of bispecific antibodies in 2+1 format established using the method according to the invention. [Figure 4] Calibration curve for the determination of avid-conjugated by-products of bispecific antibodies in TCB format established using the method according to the invention. Upper curve: spike of avid-conjugated by-products to isolated antibody; Lower curve: spike of avid-conjugated by-products in a reference material that already contains avid-conjugated by-products. [Diagram 5] SPR sensorgrams of various isolated potential by-products with increased binding valency to the first CD antigen. [Figure 6] SPR sensorgrams showing residual binding as a function of the amount of avidinoconjugated by-product. [Figure 7] When correctly assembled antibodies as well as the homodimeric avid-binding by-products were dissociated from the chip surface using an antibody-free aqueous buffer solution, a decay in the SPR (binding) signal was recorded, indicating that significant residual binding could be determined for the homodimeric avid-binding by-products. [Figure 8] Decay of SPR signal for samples containing 1% (w / w) avidin-conjugated byproduct (1 nM byproduct added to 100 nM correctly conjugated antibody). [Figure 9]A calibration curve determined using the method according to the invention by adding known amounts of homodimeric avidin-binding by-product to a sample of isolated, correctly assembled heterodimeric affin-binding antibody; various standards were prepared and a calibration curve was generated - the calibration curve is linear up to a homodimeric by-product content of at least 2% (w / w). EXAMPLES
[0169] Description of the embodiment Example 1 Determination of avidin binding by-products using the method according to the invention: 2+1-format / anti-Abeta / TfR bispecific antibody A BIAcore CAP chip (Cytiva) was docked to a BIAcore T200 instrument and prepared according to the instructions provided by the vendor. Then, multiple assay cycles were performed. Every cycle consisted of a hybridization step according to the manufacturer's instructions to bind the streptavidin on the surface of the chip. This was followed by injection of a 1 μM biotinylated transferrin receptor solution at a flow rate of 5 μl / min for 180 s. The sample was then injected into the flow chamber at a flow rate of 30 μl / min for 180 s (binding phase) and then dissociated from the transferrin receptor by switching to buffer at the same flow rate for 600 s. Finally, the surface of the chip was regenerated using the solution included in the SA CAP kit.
[0170] Successive cycles performed as described above used a range of antibody-antibody by-product mixtures as samples (0%, 1%, 2%, 3%, 4%, 5%, 10%, 20%, 50% and 100% antibody by-product). The resulting signals were processed using the BIAcore T200 evaluation software. Using the "Results Plot" function, the capture levels were adjusted and the reported signals were linearly fitted for 10 seconds before the end of the dissociation phase.
[0171] The assay was performed at 25°C using HBS-EP+ buffer (aqueous buffer solution containing 0.1 M HEPES, 1.5 M NaCl, 0.03 M EDTA, 0.5% (v / v) surfactant P20, pH 7.4) as running buffer and sample buffer.
[0172] Example 2 Determination of abiding by-products using the method according to the invention: TCB-format For quantification of small amounts of bivalent CD3-binding homodimer by-products, a BIAcore T200 was used. CD3 antigen was immobilized by amine coupling onto a CM5 chip (CD3 antigen stock solution was diluted to a concentration of 10 μg / mL in 10 mM sodium acetate buffer at pH 5.0) to >6000 RU. After immobilization, analysis was performed at 37° C. using HBS-P+ (aqueous buffer containing 0.1 M HEPES, 1.5 M NaCl, 0.5% (v / v) surfactant P20, pH 7.4) as running and dilution buffer. Samples to be analyzed were diluted to an antibody concentration of 100 nM. Calibration standards were prepared as follows: a defined amount of by-product was added to 100 nM samples (e.g., 0.25%, 0.5%, 1%, 2% knob-knob homodimer (KK) species). Samples and calibration standards were injected over the CD3-derivatized chip surface for 480 seconds. After a dissociation time of 1200 s at a flow rate of 20 μl / min, the surface was regenerated with 3M MgCl 2 A 60 s regeneration step with solution followed. Data were analyzed using BiaEvaluation software with concentration analysis using the Calibration function. Calibration settings are specified as follows: Flow cell: FC2-1 or FC4-3, Report point: Stability at 1200 s, Response type: Relative response, Fitting function: Linear. Quantification is performed by calibration by standard addition. % values of homodimeric CD3: KK equivalent = intercept / slope.
[0173] Example 3 Determination of avidin-linked by-products using the method according to the invention: CrossMab format For the quantification of small amounts of the first CD antigen-bound homodimer by-product, a BIAcore T200 was used. The first CD antigen was immobilized at a level of 2000RU-4000RU on the SA chip at a flow rate of 10 μL / min (the first CD antigen stock solution was diluted to a concentration of 5 μg / mL in HBS-P+ buffer). After immobilization, the analysis was carried out at 25 °C with HBS-P+ as running and dilution buffer. The antibody sample to be analyzed was diluted to 100 nM. In parallel, several samples were prepared for calibration by standard addition: a defined amount of by-product was added to the 100 nM antibody sample (e.g., 0.25%, 0.5%, 1% and 2% of knob-knob homodimer (KK) by-product). The antibody sample and the calibration sample were injected for 480 s over the surface of the first CD antigen chip at a flow rate of 20 μL / min. After 1200 sec dissociation at a flow rate of 20 μl / min, the surface was regenerated for 120 sec with "Gentle Ag / Ab Elution Buffer pH 6.6" (Thermo Cat. No. 21013). Data Analysis: Data were analyzed using BiaEvaluation software with concentration analysis using the Calibration function. Calibration settings are specified as follows: Flow cell: FC2-1 or FC4-3, Report point: Stability at 1200 sec, Response type: Relative response, Fitting function: Linear. Quantification is performed by calibration with standard addition. % values of homodimeric KK first CD antigen: KK equivalent = intercept / slope.
Claims
1. 1. A method for determining avid-binding by-products of a bispecific antibody in a sample containing a properly assembled bispecific antibody and one or more avid-binding by-products of said bispecific antibody using surface plasmon resonance, comprising: The correctly assembled bispecific antibody comprises one or more binding sites for a first antigen and one or more binding sites for a second antigen; the avid-conjugated by-product of the bispecific antibody contains two or more, and more, binding sites for the first antigen than the properly assembled bispecific antibody; The method comprises: i) applying a loading solution containing the correctly assembled bispecific antibody to an SPR surface on which the first antigen is immobilized at at least 1000 RU to generate an SPR signal, then applying a dissociation solution that does not contain a compound that binds to the first antigen to the SPR chip and recording the decay of the SPR signal; ii) applying a sample solution suspected of containing an avidin-binding by-product of the bispecific antibody to an SPR surface on which the first antigen is immobilized at at least 1000 RU to generate an SPR signal, and then applying a dissociation solution that does not contain a compound that binds to the first antigen to the SPR chip and recording the decay of the SPR signal; iii) determining the avidin-binding by-products of the bispecific antibody when the decay of the SPR signal determined in step ii) is slower than the decay of the SPR signal determined in step i); A method comprising:
2. The method of claim 1 , wherein the first antigen is immobilized at at least 2000 RU.
3. The method of claim 1 or 2, wherein the first antigen is immobilized at 2000 RU or more and 8000 RU or less.
4. The method according to any one of claims 1 to 3, wherein the application of the loading solution and / or the sample is for at least 300 seconds at a flow rate of between 5 μL / min and 50 μL / min.
5. The method according to any one of claims 1 to 4, wherein the application of the loading solution and / or the sample is for at least 400 seconds at a flow rate of between 5 μL / min and 50 μL / min.
6. 6. The method of any one of claims 1 to 5, wherein the application of the dissociation solution is for at least 600 seconds at a flow rate of 5 μL / min to 50 μL / min.
7. 7. The method of any one of claims 1 to 6, wherein the application of the dissociation solution is for at least 1200 seconds at a flow rate of 5 μL / min to 50 μL / min.
8. The method according to any one of claims 1 to 5, wherein the application of the loading solution and the sample is under the same conditions.
9. The method according to any one of claims 1 to 3 and 6 to 8, wherein the application of the dissociation solution in steps i) and ii) is under the same conditions.
10. The method of any one of claims 4 to 9, wherein the flow rate is between 15 μL / min and 35 μL / min.
11. The method according to any one of claims 1 to 10, wherein the determination in step iii) is based on the SPR signal determined at a time point at least 400 seconds after the start of the application of the dissociation solution, and the SPR signal obtained with the loading solution at the start of the application of the dissociation solution in steps i) and ii) is made identical.
12. The method according to any one of claims 1 to 6 and 8 to 11, wherein the determination in step iii) is based on the SPR signal determined at a time point at least 1200 seconds after the start of the application of the dissociation solution, and the SPR signal obtained with the loading solution at the start of the application of the dissociation solution in steps i) and ii) is made identical.
13. The antibody, i) bispecific antibodies in CrossMab format, or ii) a bispecific antibody in TCB format, or iii) Bispecific antibodies in 2+1 format The method according to any one of claims 1 to 12, wherein
14. The method of any one of claims 1 to 13 for determining the presence of antibody-related homodimeric avidin-linked by-products.
15. The method of any one of claims 1 to 13 for quantifying the presence of antibody-related homodimeric abiding by-products.
Citation Information
Patent Citations
Human fcrn binding modified antibody and method of use
JP2016528167A
spr-based cross-linking assays to determine the biological activity of multivalent multispecific molecules
JP2016540212A
Method for detecting light chain mispairing of a multispecific antibody
JP2017509669A
Determination of purity of multimeric proteins
JP2018528389A
Purification of FKPA and its use for the production of recombinant polypeptides
JP2018533355A
